Skip to main content
. 2021 Jul 14;8:690995. doi: 10.3389/fmed.2021.690995

Table 1.

Demographic characteristics and compliance in the FAS population.

Parameter Rabeprazole Anaprazole P-value
10 mg (n = 50) 20 mg (n = 47) 40 mg (n = 48)
Demographic and clinical characteristics
Age (mean ± SD, y) 45.1 ± 10.75 39.5 ± 12.72 41.0 ± 11.97 0.0549
Males [No. (%)] 37 (74.0) 33 (70.2) 32 (66.7) 0.7299
Height (mean ± SD, cm) 167.83 ± 7.888 166.47 ± 8.418 167.06 ± 8.156 0.7117
Weight(mean ± SD, kg) 65.70 ± 12.251 62.64 ± 10.518 63.34 ± 9.540 0.3455
BMI (mean ± SD, kg/m2) 23.17 ± 3.456 22.49 ± 3.031 22.60 ± 2.562 0.4934
PU history [No. (%)] 25 (50.0) 21 (44.7) 22 (45.8) 0.8575
Other digestive disease [No. (%)] 41 (82.0) 37 (78.7) 37 (77.1) 0.8294
PU-related drug use history over 4 weeks [No. (%)] 7 (14.0) 5 (10.6) 11 (22.9) 0.2481
PU-related surgery history [No. (%)] 0 1 (2.1) 1 (2.1) 0.9982
H. pylori status, positive [No. (%)] 40 (80.0) 37 (78.7) 38 (79.2) 0.9876
Endoscopic findings
Number of ulcers
   1 36 (72.0) 38 (80.9) 39 (81.3) 0.4613
   2 14 (28.0) 9 (19.1) 9 (18.8) 0.4613
Location of ulcers: duodenal bulb 49 (98.0) 47 (100.0) 48 (100.0) 0.9959
Size of ulcer 1 (mean ± SD) (mm) 7.4 ± 3.08 6.5 ± 2.76 6.4 ± 2.31 0.1214
Stage of ulcer 1 [No. (%)]
   A1 35 (70.0) 37 (78.7) 38 (79.2) 0.4910
   A2 15 (30.0) 10 (21.3) 10 (20.8) 0.4910
Size of ulcer 2 (mean ± SD) (mm) 6.6 ± 3.33 6.2 ± 3.19 7.3 ± 2.29 0.7331
Stage of ulcer 2 [No. (%)]
   A1 9 (64.3) 7 (77.8) 7 (77.8) 0.7050
   A2 4 (28.6) 2 (22.2) 2 (22.2) 0.9191
   H1 1 (7.1) 0 0 0.9967
Drug compliance
Compliance within the acceptable range of 80–120% [No. (%)] 50 (100%) 47 (100%) 47 (97.9%) 0.9958
Actual medication in total (mean ± SD, tablet/capsule) 27.2 ± 4.03 27.4 ± 3.95 26.6 ± 5.20 0.4930
Drug exposure time (mean ± SD, day) 27.3 ± 4.03 27.4 ± 3.95 27.1 ± 4.93 0.7590
Treatment frequency (mean ± SD, tablet/capsule per day) 0.994 ± 0.023 0.999 ± 0.011 0.984 ± 0.068 0.3684

FAS, full analysis set; PU, peptic ulcer.